

8e

Degussa 


Degussa
Corporation
September 1, 1994

Contains No CBI

RECEIVED
OPPT CBIC

94 SEP -7 AM 11: 28

Document Processing Center (TS-790) A
Attn: Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
Environmental Protection Agency
401 M Street, S. W.
Washington, D.C. 20460



ORIGINAL

Re: Substantial Risk Notification
Pursuant to TSCA Section 8(e)

Dear Sir:

This Substantial Risk Notification is being submitted in accordance with Section 8(e) of the Toxic Substances Control Act (TSCA) by Degussa Corporation. The chemical substance is Methanesulfinic acid, aminoimino- (which we call Formamidine Sulfinic Acid or "FAS"), CASRN 1758-73-2. We import this chemical substance.

We just became aware of an micronucleus test in mice performed in Austria as a part of the Organization of Economic Cooperation and Development (OECD) high production volume program for existing chemicals. Austria is the sponsor country. We are aware that the EPA is involved with the Screening Information Data Sets Program (SIDS), but we are of the opinion that we need to report this result under TSCA Section 8(e) if we became aware of the result before it was published even though the EPA may also be aware of the result.

Summary of Results.

Aminoimino methanesulfinic acid was administered orally to mice (CrI: NMRI BR) at a dose of 600 mg/kg body weight. The animals were killed after 24, 48 and 72 hours. The amount of micronucleated polychromatic erythrocytes was significantly increased in all of the groups compared with the negative control group. The decrease of nucleated cells indicate a cytotoxic effect. The number of polychromatic erythrocytes was also decreased.

The report is marked confidential. Please let us know whether we should try to obtain approval from the sponsor of the study to submit it to the EPA. This may not be necessary because it is likely that the EPA either has a copy or will receive it as part of the SIDS program.

Sincerely,

John Lewinson

John Lewinson, Ph.D.
Manager, Product Regulatory Compliance



JL-94-372

cc: R. Marion, DCA
R. Wardell, DCRP
B. Santoro, DCRP

